Logo image of CGTX

COGNITION THERAPEUTICS INC (CGTX) Stock Fundamental Analysis

NASDAQ:CGTX - US19243B1026 - Common Stock

2.5264 USD
-0.53 (-17.44%)
Last: 8/28/2025, 12:06:09 PM
Fundamental Rating

2

CGTX gets a fundamental rating of 2 out of 10. The analysis compared the fundamentals against 193 industry peers in the Pharmaceuticals industry. While CGTX seems to be doing ok healthwise, there are quite some concerns on its profitability. CGTX is valued expensive and it does not seem to be growing.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

CGTX had negative earnings in the past year.
CGTX had a negative operating cash flow in the past year.
In the past 5 years CGTX always reported negative net income.
CGTX had a negative operating cash flow in each of the past 5 years.
CGTX Yearly Net Income VS EBIT VS OCF VS FCFCGTX Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2019 2020 2021 2022 2023 2024 -10M -20M -30M -40M -50M

1.2 Ratios

Looking at the Return On Assets, with a value of -168.14%, CGTX is doing worse than 86.53% of the companies in the same industry.
With a Return On Equity value of -469.38%, CGTX is not doing good in the industry: 77.72% of the companies in the same industry are doing better.
Industry RankSector Rank
ROA -168.14%
ROE -469.38%
ROIC N/A
ROA(3y)-76.04%
ROA(5y)-85.03%
ROE(3y)-113.24%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
CGTX Yearly ROA, ROE, ROICCGTX Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2019 2020 2021 2022 2023 2024 0 100 -100 -200 -300

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for CGTX so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
CGTX Yearly Profit, Operating, Gross MarginsCGTX Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2019 2020 2021 2022 2023 2024

More info and screens

5

2. Health

2.1 Basic Checks

The number of shares outstanding for CGTX has been increased compared to 1 year ago.
Compared to 5 years ago, CGTX has more shares outstanding
CGTX has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
CGTX Yearly Shares OutstandingCGTX Yearly Shares OutstandingYearly Shares Outstanding 2019 2020 2021 2022 2023 2024 10M 20M 30M 40M 50M
CGTX Yearly Total Debt VS Total AssetsCGTX Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2019 2020 2021 2022 2023 2024 10M 20M 30M 40M 50M

2.2 Solvency

Based on the Altman-Z score of -11.37, we must say that CGTX is in the distress zone and has some risk of bankruptcy.
CGTX has a worse Altman-Z score (-11.37) than 70.98% of its industry peers.
CGTX has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -11.37
ROIC/WACCN/A
WACCN/A
CGTX Yearly LT Debt VS Equity VS FCFCGTX Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2019 2020 2021 2022 2023 2024 0 20M -20M 40M

2.3 Liquidity

A Current Ratio of 1.54 indicates that CGTX should not have too much problems paying its short term obligations.
CGTX has a Current ratio of 1.54. This is in the lower half of the industry: CGTX underperforms 66.84% of its industry peers.
CGTX has a Quick Ratio of 1.54. This is a normal value and indicates that CGTX is financially healthy and should not expect problems in meeting its short term obligations.
CGTX has a Quick ratio of 1.54. This is comparable to the rest of the industry: CGTX outperforms 41.45% of its industry peers.
Industry RankSector Rank
Current Ratio 1.54
Quick Ratio 1.54
CGTX Yearly Current Assets VS Current LiabilitesCGTX Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2019 2020 2021 2022 2023 2024 10M 20M 30M 40M 50M

More info and screens

1

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 28.72% over the past year.
EPS 1Y (TTM)28.72%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%38.89%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

The Earnings Per Share is expected to grow by 12.63% on average over the next years. This is quite good.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y50.76%
EPS Next 2Y31.99%
EPS Next 3Y19.24%
EPS Next 5Y12.63%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
CGTX Yearly Revenue VS EstimatesCGTX Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2028 2029 2030 2031 2032 100M 200M 300M 400M
CGTX Yearly EPS VS EstimatesCGTX Yearly EPS VS EstimatesYearly EPS VS Estimates 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 0 -0.5 -1 -1.5

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

CGTX reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for CGTX. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
CGTX Price Earnings VS Forward Price EarningsCGTX Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 10 -10 20

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
CGTX Per share dataCGTX EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 -0.2 -0.4 -0.6

4.3 Compensation for Growth

A more expensive valuation may be justified as CGTX's earnings are expected to grow with 19.24% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y31.99%
EPS Next 3Y19.24%

More info and screens

0

5. Dividend

5.1 Amount

CGTX does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

COGNITION THERAPEUTICS INC

NASDAQ:CGTX (8/28/2025, 12:06:09 PM)

2.5264

-0.53 (-17.44%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)08-07 2025-08-07/amc
Earnings (Next)11-11 2025-11-11
Inst Owners18.72%
Inst Owner Change-3.46%
Ins Owners0.97%
Ins Owner Change4.43%
Market Cap185.61M
Analysts82
Price Target3.32 (31.41%)
Short Float %7.3%
Short Ratio0.48
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-12.8%
Min EPS beat(2)-24.49%
Max EPS beat(2)-1.1%
EPS beat(4)0
Avg EPS beat(4)-12.97%
Min EPS beat(4)-24.49%
Max EPS beat(4)-1.1%
EPS beat(8)3
Avg EPS beat(8)-0.34%
EPS beat(12)6
Avg EPS beat(12)2.96%
EPS beat(16)8
Avg EPS beat(16)-345.68%
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)-39.81%
EPS NQ rev (1m)-11.11%
EPS NQ rev (3m)37.5%
EPS NY rev (1m)-2.44%
EPS NY rev (3m)-3.51%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 26.41
P/tB 26.41
EV/EBITDA N/A
EPS(TTM)-0.67
EYN/A
EPS(NY)-0.22
Fwd EYN/A
FCF(TTM)-0.42
FCFYN/A
OCF(TTM)-0.42
OCFYN/A
SpS0
BVpS0.1
TBVpS0.1
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -168.14%
ROE -469.38%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-76.04%
ROA(5y)-85.03%
ROE(3y)-113.24%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 1.54
Quick Ratio 1.54
Altman-Z -11.37
F-Score4
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)90.78%
Cap/Depr(5y)63.13%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)28.72%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%38.89%
EPS Next Y50.76%
EPS Next 2Y31.99%
EPS Next 3Y19.24%
EPS Next 5Y12.63%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y9.84%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-84.37%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-85.36%
OCF growth 3YN/A
OCF growth 5YN/A